Blincyto approved in Europe for newly diagnosed adults with B-ALL
The European Commission has approved Blincyto (blinatumomab) as part of a consolidation therapy regimen to reduce the risk of relapse in adults newly diagnosed…
The European Commission has approved Blincyto (blinatumomab) as part of a consolidation therapy regimen to reduce the risk of relapse in adults newly diagnosed…
The U.S. Food and Drug Administration (FDA) has approved Grafapex (treosulfan), an injectable chemotherapy, as part of the drug regimen for adults and…
The U.S. Food and Drug Administration (FDA) has approved AstraZeneca’s Calquence (acalabrutinib) as a treatment for mantle cell lymphoma (MCL), a rare and…
The U.S. Food and Drug Administration (FDA) has granted fast track designation to Puretech Health’s LYT-200, an investigative treatment for acute myeloid leukemia…
Treatment with the antipsychotic medication clozapine may increase the risk of blood cancers, but their overall likelihood is still low in people taking the drug,…
Treatment with Zynlonta (loncastuximab tesirine) is helping to push high-risk follicular lymphoma and marginal zone lymphoma into complete remission for a majority of the…
In people with acute myeloid leukemia (AML), changes in the gene profile of blood-forming stem cells, leading to a more youthful blood cell profile, could…
The U.S. Food and Drug Administration (FDA) has approved an oral liquid formulation of imatinib, now called Imkeldi, to treat specific forms of…
The U.S. Food and Drug Administration (FDA) has approved revumenib, now called Revuforj, as an oral therapy for children and adults, ages 1 year and…
The U.S. Food and Drug Administration (FDA) has approved the cell therapy Aucatzyl (obecabtagene autoleucel) to treat adults with relapsed or refractory precursor B-cell acute…